Selective β1-adrenoreceptor blocking activity of newly synthesized acyl amino-substituted aryloxypropanolamine derivatives, DPJ 955 and DPJ 890, in rats

Journal of Pharmacy and Pharmacology

Volumn 57, Issue 4, 2005, Pages 515-520

  Nandakumar, K ^a   Bansal, S K ^a   Singh, Randhir ^a   Bodhankar, S L ^a   Jindal, D P ^b   Coumar, Mohane S ^b   Balaraman, R ^c   Bhardwaj, S H ^d  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

^c Department of Pharmacology   (India)

^d Serum Institute of India Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DPJ 890; DPJ 955; ISOPRENALINE; N [4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY)PHENYL] 3,4 DIMETHOXYBENZAMIDE OXALATE; N [5 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY)NAPHTHALEN 1 YL]ACETAMIDE OXALATE; PROPANOLAMINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; COLON; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HEART RIGHT ATRIUM; HYPOTENSION; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; TACHYCARDIA; UTERUS;

ACETAMIDES; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; ATRIAL FUNCTION, RIGHT; BENZAMIDES; BLOOD PRESSURE; COLON; FEMALE; HEART ATRIA; HEART RATE; ISOPROTERENOL; MALE; OXALATES; PROPRANOLOL; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA-1; UTERUS;

EID: 17144382451     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357055768     Document Type: Article

References (14)

1. Anonymous (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Arch. Intern. Med. 157: 2413-2446
2. Anonymous (1999) 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. 17: 151-183
3. Arunlakshana, O., Schild, H. O. (1959) Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14: 48-57
4. Chiu, C. C., Lin, Y. T., Tsai, C. H., Liang, J. C., Chiang, L. C., Wu, J. R., Chen, I. J., Yeh, J. L. (2000) Pharmacological effects of an aldehyde type alpha/beta adrenoreceptor-blocking agent with vasodilating properties. Gen. Pharmacol. 34: 391-400
5. Hjalmarson, A. (2000) Cardio protection with β adrenoreceptor blockers. Does lipophilicity matter. Basic Res. Cardiol. 95 (Suppl. 1): 141-145
6. th edn. McGraw Hill, New York, pp 215-267
7. 2-adrenergic receptor binding studies of 4-acyl amino-substituted phenoxypropanolamine and 5-acyl amino-substituted naphthyloxypropanolamine derivatives. Arzneimittelforschung 52: 654-663
8. th edn. Lippincott Williams and Wilkins, Philadephia, pp 498-503
9. Kannan, J., Gridhar, R., Balaraman, R. (1996) Synthesis and preliminary cardiovascular activity of phenoxypropanolamines as β blockers. Indian J. Pharm. 28: 120-122
10. Piercy, V. (1988) Method for assessing the activity of drugs at beta 1- and beta 2-adrenoceptors in the same animal. J. Pharmacol. Methods 20: 125-133
11. Ramsay, L. E., Williams, B., Johnson, G. D., MacGregor, G. A., Paston, L., Putter, J. F., Poulter, N., Russell, G. (1999) Guidelines for the management of hypertension: report of the third working party of the British Hypertension Society. J. Hum. Hypertens. 13: 569-592
12. Rohrer, D. K., Desai, K. H., Jasper, J. R., Stevens, M. E., Regula, D. P., Barsh, G. S., Bernstein, D., Kobilka, B. K. (1996) Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl Acad. Sci. USA 93: 7375-7380
13. Staessen, J. A., Wang, J. G., Thijis, L. (2001) Cardiovascular protection and blood pressure: a meta-analysis. Lancet 358: 1305-1315
14. Wellstein, A., Belz, G. G., Butzer, R., Polsak, R., Pett, B. (1988) Beta adrenoreceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots. J. Pharmacol. Exp. Ther. 246: 328-337